Literature DB >> 29352481

Aprepitant did not modify global disease activity in cutaneous T-cell lymphomas.

L Maroñas-Jiménez1, P L Ortiz-Romero1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29352481     DOI： 10.1111/bjd.16374

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  1 in total

1.  Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.

Authors:  C Le Gall-Ianotto; R Verdet; E Nowak; L Le Roux; A Gasse; A Fiedler; D Carlhant-Kowalski; P Marcorelles; L Misery; J C Ianotto
Journal:  Trials       Date:  2021-12-19       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.